Comments
Loading...

Recursion Pharmaceuticals

RXRXNASDAQ
Logo brought to you by Benzinga Data
$6.91
0.152.22%
At Close: -
$6.91
00.00%
After Hours: 6:04 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$33.00
Lowest Price Target1
$6.00
Consensus Price Target1
$12.00

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock, Analyst Ratings, Price Targets, Forecasts

Recursion Pharmaceuticals Inc has a consensus price target of $12 based on the ratings of 11 analysts. The high is $33 issued by Berenberg on July 12, 2023. The low is $6 issued by Jefferies on September 3, 2024. The 3 most-recent analyst ratings were released by Needham, Jefferies, and Leerink Partners on September 4, 2024, September 3, 2024, and September 3, 2024, respectively. With an average price target of $8.33 between Needham, Jefferies, and Leerink Partners, there's an implied 20.60% upside for Recursion Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Jun
1
Jul
0
0
0
0
Aug
1
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.4
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
Jefferies
Leerink Partners
Keybanc
JP Morgan

1calculated from analyst ratings

Analyst Ratings for Recursion Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Recursion Pharmaceuticals (RXRX) stock?

A

The latest price target for Recursion Pharmaceuticals (NASDAQ:RXRX) was reported by Needham on September 4, 2024. The analyst firm set a price target for $11.00 expecting RXRX to rise to within 12 months (a possible 59.19% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Recursion Pharmaceuticals (RXRX)?

A

The latest analyst rating for Recursion Pharmaceuticals (NASDAQ:RXRX) was provided by Needham, and Recursion Pharmaceuticals maintained their buy rating.

Q

When was the last upgrade for Recursion Pharmaceuticals (RXRX)?

A

There is no last upgrade for Recursion Pharmaceuticals

Q

When was the last downgrade for Recursion Pharmaceuticals (RXRX)?

A

The last downgrade for Recursion Pharmaceuticals Inc happened on April 18, 2022 when B of A Securities changed their price target from N/A to N/A for Recursion Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for Recursion Pharmaceuticals (RXRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Recursion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Recursion Pharmaceuticals was filed on September 4, 2024 so you should expect the next rating to be made available sometime around September 4, 2025.

Q

Is the Analyst Rating Recursion Pharmaceuticals (RXRX) correct?

A

While ratings are subjective and will change, the latest Recursion Pharmaceuticals (RXRX) rating was a maintained with a price target of $16.00 to $11.00. The current price Recursion Pharmaceuticals (RXRX) is trading at is $6.91, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch